1516PHYPOMAGNESAEMIA IN CANCER PATIENTS: UNDERESTIMATED PROBLEM? WHEN SUPPORTIVE CARE IS DETRIMENTAL: THE EXAMPLE OF PROTONIC PUMP INHIBITORS

ABSTRACT Aim: Magnesium ( Mg) is an important cofactor for many enzymes and metabolic reactions. Serum Mg levels Methods: We analyzed a total of 168 patients (age: 39- 84 years, median age: 68 aa) in actual active treatment and concomitant PPI. We stratified them according to diagnosis, cancer protocol, stage of disease, comorbidities (particulary renal failure) and other drugs. Results: 23 (11 of them with metastatic disease) out of the 168 pazients in PPI treatment (13.7%) had hypomagnesemia (range: 1.2 mg/dl -1.6 mg/dl nv : 1.8-2.5 ). Of the 23 patients: 2 assumed diuretics, 1 was under cisplatin, 1 oxaliplatin and 2 zoledronic acid. Diagnosis included: 7 breast cancers, 5 lung cancers, 2 colon cancers, 1 prostate cancer, 3 lymphoma, 2 myeloma, 1Kidney,1 pancreas, 1 liver cancer. In the other 17 patients (10.1% ) no other causes were identified. Of these 17 patients : 8 had metastatic disease. Common feature of this hypoMg was its persistence notwithstanding supplementation with oral or ev magnesium and dietary advice. Patients common complaints were : fatigue and muscle weakness, irritability, insomnia. No relevant abnormality in ECG. Conclusions: PPI are commonly used in oncology but related hypomagnesemia is probably underestimated and many common symptoms as fatigue but also neuropathy might be worsened by it. Taking into account this problem might easily improve the QoL of our patients. Not everything that happens in a cancer patient is cancer related. Disclosure: All authors have declared no conflicts of interest.